The Technical Analyst
Edwards Lifesciences Corp [EW]
Exchange: NYSE Sector: Healthcare Industry: Medical Devices
Edwards Lifesciences Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.81% $87.48
America/New_York / 9 mai 2024 @ 15:53
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 52 715 mill |
| EPS: | 2.32 |
| P/E: | 37.71 |
| Earnings Date: | Jul 24, 2024 |
| SharesOutstanding: | 602.60 mill |
| Avg Daily Volume: | 3.42 mill |
| RATING 2024-05-09 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.44x |
| Company: PE 37.71 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 37.71 | industry: PE -41.13 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$41.89 (-52.11%) $-45.59 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 85.35 - 89.67 ( +/- 2.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-04 | Zovighian Bernard J | Buy | 6 265 | Common Stock |
| 2024-05-04 | Zovighian Bernard J | Sell | 3 718 | Common Stock |
| 2024-05-03 | Zovighian Bernard J | Sell | 527 | Common Stock |
| 2024-05-06 | Zovighian Bernard J | Buy | 580 | Common Stock |
| 2024-05-04 | Zovighian Bernard J | Sell | 6 265 | Performance Rights |
| INSIDER POWER |
|---|
| -24.69 |
| Last 99 transactions |
| Buy: 282 758 | Sell: 464 323 |
Forecast:
16:00 - $87.50
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $87.50
Forecast 2: 16:00 - $87.50
Forecast 3: 16:00 - $87.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $87.48 (2.81% ) |
| Volume | 2.67 mill |
| Avg. Vol. | 3.42 mill |
| % of Avg. Vol | 78.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest Press Releases
2024-04-25 16:15:00 - Press Release
Edwards Lifesciences Reports First Quarter Results
Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) today reported financial results for the quarter ended march 31, 2024. highlights and outlook q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion q1 tavr sales grew 6%; constant currency sales grew 8% adjusted for billing days q1 tmtt sales grew 75% q1 eps of $0.58; adjusted1 eps of $0.66 raising 2024 sales guidance to the high end of previous 8 to 10%1 range raising full-year 2024 sales guidance for tmtt.
2024-04-18 07:10:00 - Press Release
Edwards Lifesciences To Host Earnings Conference Call On April 25, 2024
Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) plans to announce its operating results for the quarter ended march 31, 2024 after the market closes on thursday, april 25, 2024, and will host a conference call at 5:00 p.m. et that day to discuss those results. to participate in the conference call, dial (877) 704-2848 or (201) 389-0893. the call will also be available live and archived on the “investor relations” section of the edwards website at ir.edwards.com. about edwards l.
2024-04-07 16:30:00 - Press Release
Study Of Nfl Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
Atlanta--(business wire)--edwards lifesciences (nyse: ew) announced the release of data from the huddle study that examined the prevalence of heart disease and associated risk factors among members of the national football league (nfl) alumni association and their families. the findings of this study, which identified a significant discrepancy between participant self-awareness and actual prevalence of heart disease and associated risk factors, were presented today during a late-breaking clinic.
2024-03-11 14:00:00 - Press Release
Large, Real-world Studies Demonstrate Continued Excellent Outcomes For Patients Receiving Edwards Sapien Tavr
Washington--(business wire)--edwards lifesciences (nyse: ew) announced today at cardiovascular research technologies (crt) 2024 the compelling results from two large, real-world studies based on tvt registry data that demonstrated continued excellent outcomes for patients treated with the edwards sapien valve platform. a study of edwards' latest tavr technology, the sapien 3 ultra resilia valve, found lower rates of paravalvular leak (pvl) at 30 days, lower echo-derived gradients and larger eff.
2024-02-23 07:05:00 - Press Release
Edwards Lifesciences To Present At The 44th Annual Td Cowen Healthcare Conference
Irvine, calif.--(business wire)--edwards lifesciences corporation (nyse: ew) today announced it will participate in the td cowen healthcare conference on tuesday, march 5, 2024. bernard zovighian, chief executive officer, and scott ullem, chief financial officer, are scheduled to present at 10:30 a.m. et. a live webcast of the presentation will be available on the edwards lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. a.
Latest News
2024-05-07 12:41:37 - Zacks Investment Research
ALC vs. EW: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?
2024-05-01 10:46:38 - Zacks Investment Research
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
2024-04-30 09:56:08 - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
2024-04-29 13:20:29 - Zacks Investment Research
Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
2024-04-26 12:11:03 - Zacks Investment Research
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
2024-04-25 19:01:28 - Zacks Investment Research
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-04-25 18:30:22 - Zacks Investment Research
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
Edwards Lifesciences (EW) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.62 per share a year ago.
2024-04-25 18:29:47 - Reuters
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength
Edwards Lifesciences Corp on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices.
2024-04-24 15:01:10 - Zacks Investment Research
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
2024-04-22 10:22:21 - Zacks Investment Research
Unveiling Edwards Lifesciences (EW) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.